BIO-TECHNE Corp (TECH) stock forecast and price target
Price $72.80 · data as of November 13, 2026
12-month price target
Gold marker: average target · white marker: today’s price ($72.80)
Analyst ratings
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends June 30, 2027 | $2.03 | +5.2% | $1.3B |
| Next fiscal year ends June 30, 2028 | $2.31 | +13.8% | $1.4B |
| Next quarter ends December 31, 2026 | $0.47 | +2.1% | $308M |
| Quarter after ends March 31, 2027 | $0.55 | +3.9% | $327M |
Consensus of the analysts covering BIO-TECHNE, updated daily. In the last 30 days 0 estimates were raised and 1 lowered.
Our model vs. Wall Street
Analysts see 3.2% downside over 12 months. Our discounted cash flow model with moderate assumptions puts BIO-TECHNE’s intrinsic value about 60% below today’s market value, and it scores 2.6 out of 5 on our checks. Price targets follow sentiment; a DCF follows cash. When both point the same way the signal is stronger. Try your own assumptions.
Frequently asked questions
What is the BIO-TECHNE stock price target?
The average 12-month target from 10 analysts is $70.50, 3.2% below the current price of $72.80 Targets range from $50.00 to $73.00.
Is BIO-TECHNE a buy according to analysts?
The consensus rating is “Hold” (12 hold, 1 sell). Ratings are opinions, not guarantees; this is not investment advice.
How much is BIO-TECHNE expected to earn?
Analysts expect EPS of $2.03 for the fiscal year ending June 30, 2027 and $2.31 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.